Diligence memo · auto-generated · as of July 3, 2026
BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
BioRestorative Therapies, Inc. operates in Biotechnology, based in Melville.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BioRestorative Therapies, Inc. has raised $20M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $14M on 2014-01-14.
Most recent recorded round closed around 2025-10-08.
Valuation (modeled)modeled
Provath models BioRestorative Therapies, Inc. at approximately $4.0M (range $1.5M–$6.4M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.25× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era. Issuer reports $0–$1M revenue while modeled below niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 9.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotechnology peers (4293 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.